Detects human Siglec‑1/CD169 in direct ELISAs and Western blots. In direct ELISAs, approximately 20% cross-reactivity with recombinant mouse Siglec-1 is observed and less than 1% cross-reactivity with recombinant human Siglec-2 is observed.
Polyclonal Sheep IgG
Mouse myeloma cell line NS0-derived recombinant human Siglec‑1/CD169 Ser20-Gln1641 Accession # Q9BZZ2
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Measured by its ability to neutralize Siglec‑1/CD169-mediated adhesion of human red blood cells. Kelm, S. et al. (1994) Current Biology 4:965. The Neutralization Dose (ND50) is typically 1.5-7.5 µg/mL in the presence of 5 µg/mL Recombinant Human Siglec‑1/CD169 Fc Chimera.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Detection of Human Siglec‑1 by Western Blot.
Western blot shows lysates of SH‑SY5Y human neuroblastoma cell line and mouse lymph node tissue. PVDF membrane was probed with 1 µg/mL of Sheep Anti-Human Siglec‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5197) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for Siglec‑1 at approximately 180 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.
Cell Adhesion Mediated by Siglec‑1/CD169 and Neutralization by Human Siglec‑1/CD169 Antibody.
Recombinant Human Siglec‑1/CD169 Fc Chimera (Catalog # 5197-SL), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human Siglec‑1/CD169 Fc Chimera (5 µg/mL) is neutralized (green line) by increasing concentrations of Sheep Anti-Human Siglec‑1/CD169 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5197). The ND50 is typically 1.5-7.5 µg/mL.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Siglecs are sialic acid specific I-type lectins that belong to the immunoglobulin superfamily. Structurally, they are transmembrane proteins with an N-terminal Ig-like V‑set domain followed by varying numbers of Ig-like C2-set domains (1, 2). Human Siglec-1, also known as sialoadhesin and CD169, is a 175‑185 kDa glycoprotein. It contains a 1622 amino acid (aa) extracellular domain (ECD) with one Ig-like V‑set domain and 16 Ig-like C2-set domains, a 21 aa transmembrane segment, and a 44 aa cytoplasmic domain (3). Within the ECD, human Siglec-1 shares approximately 70% aa sequence identity with mouse and rat Siglec-1. Alternate splicing generates a potentially soluble form of the ECD, and a second isoform with a substituted cytoplasmic domain. Siglec-1 expression is restricted to lymph node and splenic macrophages, plus some tissue macrophages (3). The adhesive function of Siglec-1 is supported by the N-terminal Ig-like domain which shows a selectivity for alpha 2,3‑linked sialic acid residues (3‑5). Siglec-1 binds a number of sialylated molecules including the mannose receptor, MGL1, MUC1, PSGL-1, and different glycoforms of CD43 (6‑9). Its binding capacity can be masked by endogenous sialylated molecules (10, 11). The sialylated and sulfated N-linked carbohydrates that modify Siglec-1 itself are required for ligand binding (6, 7). Siglec-1 is expressed on dendritic cells following rhinovirus exposure, and these DC promote T cell anergy (12). It is also induced on circulating monocytes during systemic sclerosis and HIV-1 infection (13‑15). Siglec-1 can trap HIV-1 particles for trans infection of permissive cells (14).
Varki, A. and T. Angata (2006) Glycobiology 16:1R.
Crocker, P.R. et al. (2007) Nat. Rev. Immunol. 7:255.
Hartnell, A. et al. (2001) Blood 97:288.
Nath, D. et al. (1995) J. Biol. Chem. 270:26184.
Crocker, P.R. et al. (1991) EMBO J. 10:1661.
Martinez-Pomares, L. et al. (1999) J. Biol. Chem. 274:35211.
Kumamoto, Y. et al. (2004) J. Biol. Chem. 279:49274.
Nath, D. et al. (1999) Immunology 98:213.
van den Berg, T.K. et al. (2001) J. Immunol. 166:3637.
Nakamura, K. et al. (2002) Glycobiology 12:209.
Barnes, Y.C. et al. (1999) Blood 93:1245.
Kirchberger, S. et al. (2005) J. Immunol. 175:1145.
York, M.R. et al. (2007) Arthritis Rheum. 56:1010.
Rempel, H. et al. (2008) PloS ONE 3:e1967.
van der Kuyl, A.C. et al. (2007) Plos ONE 2:e257.
Sialic Acid Binding Ig-like Lectin 1
Entrez Gene IDs:
6614 (Human); 20612 (Mouse); 311426 (Rat)
C19orf75; CD169; Siglec1; Siglec-1; SIGLECL1 SIGLEC family like 1
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.